(Q39234435)

10 September 2017

title

A feasibility study of transdermal buprenorphine versus transdermal fentanyl in the long-term management of persistent non-cancer pain (English)

1 reference

10 September 2017

0 references

0 references

Farzana Mitra

1

1 reference

10 September 2017

Shahead Chowdhury

series ordinal

2

1 reference

10 September 2017

Mike Shelley

series ordinal

3

1 reference

10 September 2017

Gary Williams

series ordinal

4

1 reference

10 September 2017

publication date

1 January 2013

1 reference

10 September 2017

1 reference

10 September 2017

volume

14

1 reference

10 September 2017

issue

1

1 reference

10 September 2017

page(s)

75-83

1 reference

Problems and concerns of patients receiving chronic opioid therapy for chronic non-cancer pain

10 September 2017

cites work

1 reference

Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in Germany

21 January 2018

1 reference

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphon

21 January 2018

1 reference

The use of major analgesics in patients with renal dysfunction.

21 January 2018

1 reference

Allergic contact dermatitis from transdermal buprenorphine

21 January 2018

1 reference

Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study

21 January 2018

1 reference

Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine

21 January 2018

1 reference

A comparison of the skin irritation potential of transdermal fentanyl versus transdermal buprenorphine in middle-aged to elderly healthy volunteers.

21 January 2018

1 reference

Patient work in end-stage heart failure: a prospective longitudinal multiple case study.

21 January 2018

1 reference

Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study

21 January 2018

1 reference

Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine

21 January 2018

1 reference

Opioids switching with transdermal systems in chronic cancer pain.

21 January 2018

1 reference

Transdermal buprenorphine in clinical practice--a post-marketing surveillance study in 13,179 patients

21 January 2018

1 reference

Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain

21 January 2018

1 reference

Mechanisms of opioid-induced tolerance and hyperalgesia

21 January 2018

1 reference

Buprenorphine in long-term control of chronic pain in cancer patients

21 January 2018

1 reference

Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old.

21 January 2018

1 reference

Recent clinical trials of pain control: impact on quality of life

21 January 2018

1 reference

Treatment of ischemic pain in patients suffering from peripheral vasculopathy with transdermal buprenorphine plus epidural morphine with ropivacaine vs. epidural morphine with ropivacaine.

21 January 2018

1 reference

Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation

21 January 2018

1 reference

Transdermal buprenorphine - a critical appraisal of its role in pain management.

21 January 2018

1 reference

Allergic contact dermatitis due to transdermal buprenorphine

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/PME.12011

1 reference

10 September 2017

1 reference